Remnant Cholesterol Predicts High CV Death Risk in Dialysis Patients

Remnant cholesterol (RC) was examined for its relationship to chronic kidney disease severity and cardiovascular risk in two separate single-center analyses presented at ASN Kidney Week 2026 in Denver, Colorado, Pharmacy Times reported. Bai, Z. Deng, and S. Wang, identified remnant cholesterol as an independent risk factor for cardiovascular mortality among patients on maintenance hemodialysis. Researchers in that study concluded that monitoring RC could improve cardiovascular risk stratification and help guide clinical management, though the abstract expressed its RC cutoff in mmol/L rather than the mg/dL units standard in United States laboratories.

Peking University Inflammatory Index Comparisons

A second research team from Peking University Health Science Center and Peking University Third Hospital examined remnant cholesterol through an inflammatory lens, analyzing 1,644 chronic kidney disease patients treated between 2011 and 2020. This investigation, which shared several investigators with the hemodialysis study, compared C-reactive protein against two newer indicators: the remnant cholesterol inflammatory index and the CRP-triglyceride-glucose index. Advanced risk in the cohort was defined as chronic kidney disease stages 2 to 3 alongside cardiovascular-kidney-metabolic syndrome stages 3 to 4.

All three indicators increased significantly across the disease stages, but their diagnostic value varied. C-reactive protein best discriminated cardiovascular-kidney-metabolic severity with an area under the curve of 0.655, compared with 0.636 for the CRP-triglyceride-glucose index and 0.607 for the remnant cholesterol inflammatory index. However, C-reactive protein showed no significant association with chronic kidney disease risk stratification, scoring a P value of .379. Conversely, both the remnant cholesterol inflammatory index and the CRP-triglyceride-glucose index demonstrated significant linear associations with advanced chronic kidney disease risk.

Statistical models reveal divergence between traditional inflammatory markers and lipid indices

The statistical models revealed clear divergence between traditional inflammatory markers and lipid-based composite indices. The remnant cholesterol inflammatory index posted an odds ratio of 1.34 with a 95% confidence interval ranging from 1.13 to 1.59. The CRP-triglyceride-glucose index showed a stronger linear association, yielding an odds ratio of 2.17 with a 95% confidence interval spanning 1.28 to 3.79. Authors of the Peking University abstract concluded that both indices could provide superior assessment of chronic kidney disease risk compared with C-reactive protein and called for further study of their prognostic value across kidney disease etiologies.

Neither presentation established remnant cholesterol as an explicit treatment target. Both projects remain single-center analyses originating from China and published solely as meeting abstracts without peer-reviewed full-text accompaniment. The hemodialysis poster reported an unusually large hazard ratio while omitting its corresponding confidence interval. Despite these limitations, the findings add to evidence suggesting that cholesterol beyond LDL-C may matter in patients with kidney disease.

Pharmacist Evaluation of Lipid Panels

For clinical pharmacists reviewing lipid panels for patients with chronic kidney disease, remnant cholesterol is a value that can be derived at no added cost. Utilizing this metric may prompt closer attention toward triglyceride-rich lipoproteins and overall cardiovascular risk. Further investigation remains necessary to establish the prognostic value of these indices across kidney disease etiologies.

Details regarding the remnant cholesterol studies presented in Denver

What was the primary setting for these remnant cholesterol studies?

Both investigations were presented as research posters at the ASN Kidney Week 2026 conference held on October 24, 2026, in Denver, Colorado.

How many patients participated in the Peking University inflammatory index analysis?

Researchers retrospectively evaluated 1,644 patients with chronic kidney disease who received treatment between 2011 and 2020.

Are these findings currently published in a peer-reviewed journal?

No, both investigations are single-center analyses from China that remain available only as meeting abstracts without full-text peer-reviewed publication.

More on this story: Low Protein Intake and High Kidney Failure Risk in CKD